Download our whitepaper,

Understanding Attention-
Deficit/Hyperactivity Disorder
(ADHD): Epidemiology, Clinical
Implications & Strategies for
Clinical Trial Success

What's Inside:

  • Key FDA-Approved Pivotal Endpoints for ADHD Clinical Trials.
  • Optimizing Recruitment with Adaptive Trial Designs for ADHD.
  • Comprehensive Analysis of FDA-Approved ADHD Drugs.
  • How Diagnostic Criteria for ADHD Have Evolved and Impact Research.
  • Overcoming Common Pitfalls in ADHD Clinical Trials.
  • And additional insights to drive your trial’s success.

Access your complimentary whitepaper today:






    ADHD Clinical Trials

    Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that are more frequent and severe than typically observed in individuals at a comparable level of development.

    The evolving understanding of ADHD has significantly impacted clinical practice and research directions. Clinicians now adopt a more integrated approach in diagnosis and treatment, considering the individual’s life context, comorbid conditions, and unique symptom presentation. In research, there is an increasing focus on identifying endophenotypes, exploring non-pharmacological interventions, and understanding the long-term outcomes of those living with ADHD.

    Roughly

    55%

    of children with ADHD continue to experience symptoms into adulthood

    ADHD affects around

    6%

    of children worldwide

    ADHD costs the U.S. economy roughly

    $77b

    each year due to healthcare expenses, work loss, and reduced productivity

    Our clinical team has over

    120 years

    years of combined clinical trial experience